Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 150, Issue 2, 2009, Pages 239-242

  Liou, Ying Jay ^a,b   Chen, Mao Liang ^c   Wang, Ying Chieh ^c,d   Chen, Jen Yeu ^c   Liao, Ding Lieh ^e   Bai, Ya Mei ^a   Lin, Chao Cheng ^f   Chen, Tzu Ting ^c   Mo, Geng Han ^c   Lai, I Ching ^c,d  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e Pali Psychiatric Hospital   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antipsychotic; Haplotype; RGS; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PRIORITY JOURNAL; RGS9 GENE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RGS PROTEINS; SCHIZOPHRENIA; YOUNG ADULT;

MUS;

EID: 61449212073     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30796     Document Type: Article

References (10)

1. Berman DM, Gilman AG. 1998. Mammalian RGS proteins: Barbarians at the gate. J Biol Chem 273:1269-1272.
2. Kovoor A, Seyffarth P, Ebert J, Barghshoon S, Chen CK, Schwarz S, Axelrod JD, Cheyette BN, Simon MI, Lester HA, Schwarz J. 2005. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2(RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J Neurosci 25:2157-2165.
3. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: From structure to function. Physiol Rev 78:189-225.
4. Rahman Z, Gold SJ, Potenza MN, Cowan CW, Ni YG, He W, Wensel TG, Nestler EJ. 1999. Cloning and characterization of RGS9-2: A striatal-enriched alternatively spliced product of the RGS9 gene. J Neurosci 19:2016-2026.
5. Rahman Z, Schwarz J, Gold SJ, Zachariou V, Wein MN, Choi KH, Kovoor A, Chen CK, DiLeone RJ, Schwarz SC, Selley DE, Sim-Selley LJ, Barrot M, Luedtke RR, Self D, Neve RL, Lester HA, Simon MI, Nestler EJ. 2003. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 38:941-952.
6. Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJ. 1990. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther 252:810-816.
7. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S. 2007. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986.
8. Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
9. Thomas EA, Danielson PE, Sutcliffe JG. 1998. RG S9: A regulator of G-protein signalling with specific expression in rat and mouse striatum. J Neurosci Res 52:118-124.
10. Woerner MG, Kane JM, Lieberman JA, Alvir J, Bergmann KJ, Borenstein M, Schooler NR, Mukherjee S, Rotrosen J, Rubinstein M. 1991. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 11:34-42.